Overview

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Status:
Recruiting
Trial end date:
2022-09-29
Target enrollment:
Participant gender:
Summary
The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.
Phase:
Phase 1
Details
Lead Sponsor:
Insmed Incorporated
Treatments:
Moxifloxacin